TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Frequently asked questions
What sector does TG Therapeutics, Inc (TGTX) operate in?
TG Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TG Therapeutics, Inc (TGTX) current stock price?
As of the latest data, TG Therapeutics, Inc stock price is $47.94, with a previous close of $49.50. TG Therapeutics, Inc lost -$1.56 in the last trading session, representing a -3.15% loss.
What is TG Therapeutics, Inc (TGTX) current market capitalization?
TG Therapeutics, Inc market cap is approximately 7.34 billion.
What is TG Therapeutics, Inc (TGTX) Earnings Per Share (EPS)?
The trailing EPS is $2.86, and the forward EPS is $3.15.
What is TG Therapeutics, Inc (TGTX) Price-to-Earnings (P/E) ratio?
TG Therapeutics, Inc current P/E ratio is 16.76, with a forward P/E of 15.22.
What is TG Therapeutics, Inc (TGTX) EBITDA?
TG Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 21.67 million.
Does TG Therapeutics, Inc (TGTX) pay dividends?
No. TG Therapeutics, Inc does not pay a dividend.
How did TG Therapeutics, Inc (TGTX) perform in its most recent earnings report?
In the last report (June 30, 2026), TG Therapeutics, Inc posted an EPS surprise of -87.8% and a revenue surprise of 4.59%.
What is TG Therapeutics, Inc (TGTX) beta (volatility) score?
TG Therapeutics, Inc has a beta of 1.666, suggesting it is more volatile than the market.
